We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$266M
AUM Growth
+$58.2M
Cap. Flow
+$1.08M
Cap. Flow %
0.41%
Top 10 Hldgs %
51.18%
Holding
88
New
23
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$6.17M
2
CEMI
Chembio diagnostics, Inc.
CEMI
+$5.47M
3
EVDY
Everyday Health, Inc.
EVDY
+$4.74M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.54M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.97M

Top Sells

Rank Stock Value
1
RRM
RR MEDIA LTD ORD SHS (ISR)
RRM
+$8M
2
FOLD
Amicus Therapeutics
FOLD
+$3.32M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.2M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.02M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$2.96M

Sector Composition

Rank Sector Weight
1 Healthcare 86.21%
2 Miscellaneous 11.02%
3 Technology 2.54%
4 Industrials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$2.18B
$3.07M 1.15%
50,000
-80,000
-62% -$2.42M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$12.6B
$2.78M 1.04%
30,000
-34,000
-53% -$3.2M
PGNX
28
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$2.74M 1.03%
432,370
-16,515
-4% -$99.8K
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.22B
$2.44M 0.92%
+554,448
New +$2.21M
SRPT icon
30
CALL
Sarepta Therapeutics
SRPT
$2.18B
$2.44M 0.92%
39,700
-40,300
-50% -$1.22M
TSRO
31
DELISTED
TESARO, Inc.
TSRO
$2.27M 0.85%
22,700
-7,300
-24% -$682K
ASMB icon
32
Assembly Biosciences
ASMB
$516M
$2.27M 0.85%
26,184
+7,397
+39% +$571K
AERI
33
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$2.25M 0.84%
+59,600
New +$1.31M
RDUS
34
DELISTED
Radius Health, Inc.
RDUS
$2.16M 0.81%
+40,000
New +$2.03M
GHDX
35
DELISTED
Genomic Health, Inc.
GHDX
$2.08M 0.78%
72,100
+23,300
+48% +$649K
DBVT
36
DBV Technologies
DBVT
$786M
$2.04M 0.77%
+5,626
New +$1.95M
ALR
37
DELISTED
Alere Inc
ALR
$1.95M 0.73%
+45,000
New +$1.84M
EPIX
38
DELISTED
ESSA Pharma
EPIX
$1.68M 0.63%
29,335
+823
+3% +$44K
ALIM
39
DELISTED
Alimera Sciences
ALIM
$1.45M 0.55%
64,955
– –
AGIO icon
40
Agios Pharmaceuticals
AGIO
$2.01B
$1.32M 0.5%
+25,000
New +$1.09M
ACAD icon
41
CALL
Acadia Pharmaceuticals
ACAD
$4.73B
$1.27M 0.48%
+40,000
New +$1.36M
SVA
42
DELISTED
Sinovac Biotech, Ltd
SVA
$1.21M 0.45%
204,358
+71,855
+54% +$423K
ATRC icon
43
AtriCure
ATRC
$3.01B
$1.05M 0.39%
66,186
-46,737
-41% -$718K
OTLK icon
44
Outlook Therapeutics
OTLK
$166M
$1.04M 0.39%
1,534
+13
+0.9% +$8.26K
AZN icon
45
AstraZeneca
AZN
$258B
$986K 0.37%
+15,000
New +$980K
MRTX
46
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$826K 0.31%
125,000
– –
AGEN
47
Agenus
AGEN
$326M
$748K 0.28%
+5,308
New +$609K
THC icon
48
Tenet Healthcare
THC
$21.1B
$743K 0.28%
+32,809
New +$854K
EHIC
49
DELISTED
eHi Car Services Limited
EHIC
$603K 0.23%
+58,827
New +$622K
CRBP icon
50
Corbus Pharmaceuticals
CRBP
$140M
$552K 0.21%
+2,710
New +$337K
1
2
3 4

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q3 2016 Portfolio in Review

As of Q3 2016, Acuta Capital Partners held 88 positions worth $266M, up 28% from $208M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Acuta Capital Partners's Q3 2016 filing shows 23 new, 18 increased, 16 reduced and 21 closed positions. Its largest new stake was Aerie Pharmaceuticals: 280,000 shares worth $10.6M. The largest sale was RR MEDIA LTD ORD SHS (ISR), an estimated $8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Technology.

  • Acuta Capital Partners's largest Q3 2016 buy was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.
  • Acuta Capital Partners added most to Chembio diagnostics, Inc. in Q3 2016, an estimated $5.47M increase.
  • Acuta Capital Partners's biggest Q3 2016 reduction was Amicus Therapeutics, cutting an estimated $3.32M.
  • Acuta Capital Partners fully exited RR MEDIA LTD ORD SHS (ISR) in Q3 2016, selling an estimated $8M.
  • Acuta Capital Partners's ten largest holdings make up 51% of its $266M portfolio in Q3 2016.
  • Acuta Capital Partners opened 23 new positions and closed 21 in Q3 2016.
  • Acuta Capital Partners's portfolio value rose 28% quarter-over-quarter to $266M.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.